Patrick McIlvenny - 04 Jan 2023 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Role
Chief Accounting Officer
Signature
/s/ Adriana Hernandez-Capone, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
04 Jan 2023
Net transactions value
-$469,606
Form type
4
Filing time
06 Jan 2023, 16:56:48 UTC
Previous filing
14 Nov 2022
Next filing
06 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise +7,973 +320% 10,463 05 Jan 2023 Direct F1
transaction HZNP Ordinary Shares Tax liability $469,606 -4,147 -40% $113.24 6,316 05 Jan 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Restricted Stock Units (RSU) Award $0 +11,498 $0.000000 11,498 04 Jan 2023 Ordinary Shares 11,498 Direct F1, F2
transaction HZNP Restricted Stock Units (RSU) Options Exercise $0 -3,871 -100% $0.000000* 0 05 Jan 2023 Ordinary Shares 3,871 Direct F1, F3
transaction HZNP Restricted Stock Units (RSU) Options Exercise $0 -2,198 -50% $0.000000 2,198 05 Jan 2023 Ordinary Shares 2,198 Direct F1, F4
transaction HZNP Restricted Stock Units (RSU) Options Exercise $0 -1,904 -33% $0.000000 3,809 05 Jan 2023 Ordinary Shares 1,904 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each RSU represents a contingent right to receive one ordinary share of the Issuer.
F2 The RSUs vest 1/3rd annually on each anniversary of January 5, 2023.
F3 The final tranche of ordinary shares subject to the RSU vested on January 5, 2023.
F4 The remaining ordinary shares subject to the RSU vest on January 5, 2024.
F5 The remaining ordinary shares subject to the RSU vest ratably on January 5, 2024 and January 5, 2025